摘要
我们评价了用于预测主观认知损伤(SCI)、遗忘或非遗忘轻度认知障碍(aMCI患者,naMCI)进展为阿尔茨海默氏病(AD)患者的疾病状态指数(DSI)方法的性能。DSI模型根据有效的数据测量类似于诊断病例的病人,如认知测试中,APOE基因型、CSF生物标志物和MRI确诊病例。我们从DESCRIPA队列,其中非痴呆的患者(N =775)与认知功能障碍不同亚型随访1至5年开展的DSI模型数据。采用留一交叉验证对亚组分类精度的DSI进行计算。在预测发展为AD的DSI的分类准确度为0.75(AUC=0.83),在总人口中,0.70(AUC=0.77)的aMCI患者和0.71(AUC=0.76)的naMCI。大约一半的患者具有高或低的DSI值的子集,精度达到0.86(全部),0.78(aMCI患者)和0.85(naMCI)。患者的MRI或CSF生物标志物的数据是可用,得到0.78(全部),0.76(aMCI患者)和0.76(naMCI)的精确度;而对于明确的案例,精度上升到0.90(全部),0.83(aMCI患者)和0.91(naMCI)。结果表明,该DSI模型可以分辨清晰和模糊的案例,评估疾病的严重程度,并且还提供在不同的生物标志物的有效性。特定测试或生物标记物可能混淆对于个体患者的分析,联合几种不同类型的试验和生物标记物能够揭示疾病的轨迹和提高对AD发展情况的预测。
关键词: 阿尔茨海默氏病,脑脊髓液(CSF),计算机辅助诊断,痴呆,DESCRIPA,磁共振成像(MRI),轻度认知障碍(MCI)。
Current Alzheimer Research
Title:Predicting Progression from Cognitive Impairment to Alzheimer’s Disease with the Disease State Index
Volume: 12 Issue: 1
Author(s): Anette Hall, Jussi Mattila, Juha Koikkalainen, Jyrki Lotjonen, Robin Wolz, Philip Scheltens, Giovanni Frisoni, Magdalini Tsolaki, Flavio Nobili, Yvonne Freund-Levi, Lennart Minthon, Lutz Frolich, Harald Hampel, Pieter Jelle Visser and Hilkka Soininen
Affiliation:
关键词: 阿尔茨海默氏病,脑脊髓液(CSF),计算机辅助诊断,痴呆,DESCRIPA,磁共振成像(MRI),轻度认知障碍(MCI)。
摘要: We evaluated the performance of the Disease State Index (DSI) method when predicting progression to Alzheimer’s disease (AD) in patients with subjective cognitive impairment (SCI), amnestic or non-amnestic mild cognitive impairment (aMCI, naMCI). The DSI model measures patients’ similarity to diagnosed cases based on available data, such as cognitive tests, the APOE genotype, CSF biomarkers and MRI. We applied the DSI model to data from the DESCRIPA cohort, where non-demented patients (N=775) with different subtypes of cognitive impairment were followed for 1 to 5 years. Classification accuracies for the subgroups were calculated with the DSI using leave-one-out crossvalidation. The DSI’s classification accuracy in predicting progression to AD was 0.75 (AUC=0.83) in the total population, 0.70 (AUC=0.77) for aMCI and 0.71 (AUC=0.76) for naMCI. For a subset of approximately half of the patients with high or low DSI values, accuracy reached 0.86 (all), 0.78 (aMCI), and 0.85 (naMCI). For patients with MRI or CSF biomarker data available, theywere 0.78 (all), 0.76 (aMCI) and 0.76 (naMCI), while for clear cases the accuracies rose to 0.90 (all), 0.83 (aMCI) and 0.91 (naMCI). The results show that the DSI model can distinguish between clear and ambiguous cases, assess the severity of the disease and also provide information on the effectiveness of different biomarkers. While a specific test or biomarker may confound analysis for an individual patient, combining several different types of tests and biomarkers could be able to reveal the trajectory of the disease and improve the prediction of AD progression.
Export Options
About this article
Cite this article as:
Anette Hall , Jussi Mattila , Juha Koikkalainen , Jyrki Lotjonen , Robin Wolz , Philip Scheltens , Giovanni Frisoni , Magdalini Tsolaki , Flavio Nobili , Yvonne Freund-Levi , Lennart Minthon , Lutz Frolich , Harald Hampel , Pieter Jelle Visser and Hilkka Soininen , Predicting Progression from Cognitive Impairment to Alzheimer’s Disease with the Disease State Index, Current Alzheimer Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567205012666141218123829
DOI https://dx.doi.org/10.2174/1567205012666141218123829 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
Current Vascular Pharmacology Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases
Current Pharmaceutical Design Biomarkers for Alzheimer's Disease Diagnosis
Current Alzheimer Research BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets The Framingham Brain Donation Program: Neuropathology Along the Cognitive Continuum
Current Alzheimer Research Natural Products and their Derivatives as Cholinesterase Inhibitors in the Treatment of Neurodegenerative Disorders: An Update
Current Medicinal Chemistry The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential
Current Alzheimer Research The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery Synchronized Communication Between People with Dementia and their Volunteer Caregivers. A Video-Based Explorative Study on Temporal Aspects of Interaction and the Transfer to Education
Current Alzheimer Research Cerebral Collateral Circulation in Carotid Artery Disease
Current Cardiology Reviews Persistent Hiccups as an Atypical Initial Presentation of COVID-19: A Case Report
Infectious Disorders - Drug Targets Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Current Pharmaceutical Biotechnology Folate and Homocysteine Metabolism: Therapeutic Targets in Cardiovascular and Neurodegenerative Disorders
Current Medicinal Chemistry How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets